Biotechnology and pharmaceutical companies have delivered some of the strongest returns in the U.S. IPO market this year, taking attention away from artificial intelligence, aerospace and defense listings. According to Bloomberg data through July 17, biotech and pharmaceutical IPOs have generated a weighted average return of 55%, compared with a 4.4% weighted average loss for the broader U.S. IPO market after excluding blank-check companies and other financial vehicles. This performance comes as shares of the companies behind the 10 largest U.S. IPOs of 2026 have declined a weighted average of 6.3%, with investors showing growing concern that the AI rally may have become overextended. Jack Bannister, senior managing director in equity capital markets at investment bank Leerink Partners, described the current environment as the healthiest biotech IPO market seen in a long time.

The strong returns are encouraging more biotechnology companies to pursue public listings. At least six drug developers, led by Scribe Therapeutics, a developer of CRISPR-based genetic medicines, filed for IPOs this month and could price their offerings later in July or during the first half of August before the summer slowdown. The number of biotech IPOs completed in 2026 has already surpassed the eight listings recorded last year, while proceeds have exceeded $5 billion, roughly three times the previous year’s total. Parabilis Medicines, a biotechnology company specializing in rare cancer treatments, raised $770.6 million last month in the largest biotech IPO recorded to date. Veradermics, a company developing a drug for pattern hair loss, has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors this year, while Hemab Therapeutics Holdings, a biotechnology company focused on blood disorders, has more than doubled since listing in May.

Investors may view the sector’s recovery as being supported by a 13% gain in the Nasdaq Biotechnology Index this year, a more stable regulatory environment, notable clinical trial developments and renewed acquisition activity from major pharmaceutical companies. Three transactions valued at $10 billion or more were announced during the past month, including AbbVie (NYSE:ABBV), a pharmaceutical company, acquiring Apogee Therapeutics; GSK (NYSE:GSK), a pharmaceutical company, agreeing to purchase Nuvalent; and Vertex Pharmaceuticals (NASDAQ:VRTX), a pharmaceutical company, buying Crinetics Pharmaceuticals. These transactions have supported valuations and returned capital to healthcare investors, potentially giving them more money to deploy into upcoming IPOs. Seth Rubin, global head of equity capital markets at Stifel Financial, said some of the world’s largest fund groups are reallocating more capital toward healthcare as small- and mid-cap returns demonstrate potential upside. Higher interest rates could still become a headwind because they may affect how investors value biotechnology companies, although Bannister noted that the sector is currently trading independently of that pressure and in contrast with the AI investment trend.

Source link